Related Experiment Videos

Human CD8 and CD4 T cell epitopes of epithelial cancer antigens

N Sato1, Y Nabeta, H Kondo

  • 1Department of Pathology, Sapporo Medical University School of Medicine, Japan. nsatou@sapmed.ac.jp

Insights

This study identifies novel tumor antigens, F4.2 and 6-1-5 peptides, for gastric and oral cancers. These peptides show potential for developing new immunotherapies and cancer vaccines against epithelial tumors.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Research in tumor immunology has identified immunogenic peptides in melanoma, but extensive data for common epithelial tumors is lacking.
  • CD8 cytotoxic T lymphocytes (CTLs) and CD4 T cells recognize tumor-specific antigenic epitopes, offering potential for immunotherapy.

Purpose of the Study:

  • To identify and characterize novel HLA-restricted natural antigenic peptides from gastric and oral cancers for potential immunotherapy.
  • To investigate the therapeutic potential of these identified peptides in cancer treatment.

Main Methods:

  • Identification of an HLA-A31-restricted peptide (F4.2) from gastric signet ring cell carcinoma (HST-2) recognized by CD8 CTLs.
  • Determination of an HLA-DRB1*08032-restricted peptide (6-1-5) from oral squamous cell carcinoma (OSC-20) recognized by CD4 T cells using biochemical separation and mass spectrometry.
  • Evaluation of peptide-induced T cell reactivity and cytotoxic activity against cancer cells.

Main Results:

  • The F4.2 peptide, a 10-amino acid residue peptide, enhanced CD8 CTL TcHST-2 reactivity against HST-2 cells and conferred susceptibility to TcHST-2 lysis in HLA-A31-expressing cells.
  • The F4.2 peptide induced a specific CTL response in peripheral blood lymphocytes from gastric cancer patients, indicating its potential as a cancer vaccine.
  • The 6-1-5 peptide, a 16-mer derived from alpha-enolase, was identified from oral cancer cells.

Conclusions:

  • The identified F4.2 peptide represents a promising tumor rejection antigen for HLA-A31-positive gastric cancers and a potential candidate for cancer vaccines.
  • The 6-1-5 peptide from oral cancer also holds potential for immunotherapy.
  • Further research is ongoing to identify antigens for other common epithelial cancers.

Related Concept Videos